• Numerous clinical trials are conducted at the UCT Lung Institute by the Division of Dermatology in collaboration with the UCT Lung Institute (Link). Our joint initiatives seek to improve the state of care for eczema patients and give patients access to cutting-edge, in-development therapies.
  • The effectiveness and safety of topical carbohydrate-derived fulvic acid (CHD-FA) 4% cream in adolescent and adult patients with mild to moderate atopic dermatitis, as well as the long-term safety, tolerability, and efficacy of subcutaneous amlitelimab, are being assessed in the ongoing clinical trials.
  • Amlitelimab phase IIa trial, randomized, double-blind, Placebo controlled, parallel group, Multi-Centre study of an Anti-OX40L monoclonal antibody (Amlitelimab) in moderate-to-severe atopic dermatitis (NCT03754309) to evaluate the long-term safety, tolerability and efficacy of subcutaneous amlitelimab in adult participants with moderate to severe atopic dermatitis.
  • A randomised, double-blind, Parallel Group, Two Arm, Vehicle Controlled, Multi-Centre, Phase IIa Study to Evaluate the Efficacy and Safety of Topical Carbohydrate-Derived Fulvic Acid (CHD-FA) 4% Cream in Adolescent and Adult Patients with Mild to Moderate Atopic Dermatitis (CT-DP-01/21).